AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
On February 19, 2019, Pritzker signed into law a bill that raises the state minimum wage to $15 an hour by 2025, making Illinois the fifth state in the nation and first state in the Midwest to do so. The bill includes a tax credit for small businesses to help them deal with higher costs of labor and maintains the ability of restaurant owners to count tips toward pay. On April 12, 2019, Pritzker signed the Collective Bargaining Freedom Act, which protects the right of employers, employees, and their labor organizations to collectively bargain, ensuring that Illinois complies with the National Labor Relations Act. On May 17, 2019, Pritzker signed legislation to help workers exposed to toxic substances. In July 2019, Pritzker signed House Bill 2028, which passed both the Senate and House of Illinois unanimously. This bill doubles the compensation rate for families of police officers and firefighters killed in the line of duty from $10,000 to $20,000. On March 13, 2023, Pritzker signed the Paid Leave for All Workers Act, which requires employers to give employees at least an hour of paid leave for every 40 hours of work, up to 40 hours per year, which employees can use for any reason. It went into effect in 2024.
=== Operation Enduring Freedom VI, 2005–2008 === The 1st Brigade of the 82nd deployed in April 2005 in support of OEF 6, and returned in April 2006. 1st Battalion, 325th Infantry Regiment deployed in support of OEF 6 from July through November 2005. In March 2006, 3rd Battalion (General Support), 82nd Aviation was selected to augment a special operations task force using CH-47 Chinooks and UH-60 Black Hawks. The task force consisted of 75th Ranger Regiment, Special Forces, and 160th Special Operations Aviation Regiment (Airborne). 2007 February 18, seven soldiers from the task force died in a helicopter crash. The deployment would end a month later (March 2007). In January 2007, then Maj. Gen. David M. Rodriguez deployed the division headquarters to Bagram Air Base, Afghanistan, accompanied by 4th BCT and the Aviation Brigade, as Commander, Combined Joint Task Force-82 (CJTF-82) and Regional Command – East for Operation Enduring Freedom VIII. The 3d BCT, 10th Mountain Division (Light Infantry) was extended for 120 days to increase the troop strength against the Taliban spring offensive. Extended to 15-month deployment, 4th BCT, which included 1–508th Infantry Regiment, 2–508th Infantry Regiment, and 4–73rd Cavalry Regiment, 2–321st Field Artillery, and 782nd Brigade Support Battalion, was commanded by then Col. Martin P. Schweitzer and remained in Khowst Province from January 2007 until April 2008. The 2–508th IR worked to establish and maintain firebases in and around the Ghazni province while actively patrolling their operational area.
=== Gas cloud composition === Apart from MIC, based on laboratory simulation conditions, the gas cloud most likely also contained chloroform, dichloromethane, hydrogen chloride, methylamine, dimethylamine, trimethylamine, and carbon dioxide that was either present in the tank or was produced in the storage tank when MIC, chloroform, and water reacted. The gas cloud, composed mainly of materials denser than air, stayed close to the ground and spread in a southeast direction affecting the nearby communities. The chemical reactions may have produced a liquid or solid aerosol. Laboratory investigations by CSIR and UCC scientists failed to demonstrate the presence of hydrogen cyanide.
== Overdose == The median lethal dose of THC in humans is not fully known as there is conflicting evidence. A 1972 study gave up to 90 mg/kg of THC to dogs and monkeys without any lethal effects. Some rats died within 72 hours after a dose of up to 36 mg/kg. A 2014 case study based on the toxicology reports and relative testimony in two separate cases gave the median lethal dose in humans at 30 mg/kg (2.1 grams THC for a person who weighs 70 kg; 154 lb; 11 stone), observing cardiovascular death in the one otherwise healthy subject of the two cases studied. A different 1972 study gave the median lethal dose for intravenous THC in mice and rats at 30–40 mg/kg. A 2020 fact sheet published by the US Drug Enforcement Administration stated that "no deaths from overdose of marijuana have been reported."
=== Secondary ion mass spectrometry (SIMS) === After the samples are milled, elemental and isotopic analysis is performed using SIMS. After the primary ions hit the surface, secondary ions and particles are released during the bombardment of the surface. Scientists can gather comprehensive data regarding the material's composition by understanding which ions are utilized for milling and which secondary ions are released. [90]
Sources: en.wikipedia.org
== Mathematics == Chain (ordered set), a totally ordered set, usually a subset of a given partially ordered set Chain (algebraic topology), a formal linear combination of k-simplices Chain complex, a generalization of the algebraic topology construct to homological algebra Chain rule, a tool for differentiation in calculus Chain sequence, numbers in the mathematical study of continued fractions Conway chained arrow notation, a way of expressing exponents using arrows Jordan chain, a sequence of linearly independent generalized eigenvectors of descending rank Markov chain, a discrete-time stochastic process with the Markov property Pseudo-arc, which has at its heart the concept of a chain
=== Bacteria === Many common culturable laboratory strains are deep-frozen to preserve genetically and phenotypically stable, long-term stocks. Sub-culturing and prolonged refrigerated samples may lead to loss of plasmid(s) or mutations. Common final glycerol percentages are 15, 20, and 25. From a fresh culture plate, one single colony of interest is chosen and liquid culture is made. From the liquid culture, the medium is directly mixed with an equal amount of glycerol; the colony should be checked for any defects like mutations. All antibiotics should be washed from the culture before long-term storage. Methods vary, but mixing can be done gently by inversion or rapidly by vortex and cooling can vary by either placing the cryotube directly at −50 to −95 °C, shock-freezing in liquid nitrogen or gradually cooling and then storing at −80 °C or cooler (liquid nitrogen or liquid nitrogen vapor). Recovery of bacteria can also vary, namely, if beads are stored within the tube then the few beads can be used to plate or the frozen stock can be scraped with a loop and then plated, however, since only little stock is needed the entire tube should never be completely thawed and repeated freeze-thaw should be avoided. 100% recovery is not feasible regardless of methodology.
In 1905, Rafael Zerda Bayón named the active extract of ayahuasca as telepathine, a name latter used by the Colombian chemist Guillermo Fischer Cárdenas when he isolated the substance in 1932. Contemporaneously, Lewin and Gunn were independently studying the properties of the banisterine, extracted of the B. caapi, and its effects on animal models. Further clinical trials were being conducted, exploring the effects of banisterine on Parkinson's disease. Later it was found that both telepathine and banisterine are the same substance, identical to a chemical already isolated from Peganum harmala and given the name Harmine.
=== Variation === The two lobes differ slightly in size, with the left lobe usually higher than the right. Thymic tissue may be found scattered on or around the gland, and occasionally within the thyroid. The thymus in children stretches variably upwards, at times to as high as the thyroid gland.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.